HUTCHMED has announced the upcoming presentation of promising preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate (ATTC), at the AACR Annual Meeting 2026. This novel compound demonstrates potent inhibition of PI3K and PIKK family kinases, with an IC50 of approximately 1 to 10 nM, and shows excellent selectivity across 418 kinases. The ATTC platform combines a highly selective PI3K/PIKK payload with an anti-EGFR antibody, facilitating targeted delivery and robust anti-tumor effects, particularly in EGFR-expressing cancer cells.

The significance of these findings lies in HMPL-A580’s potential to overcome common challenges faced by existing PAM-targeted therapies, such as on-target toxicities and insufficient tumor-specific delivery. The preclinical data indicate that HMPL-A580 effectively induces apoptosis in tumor cells with high EGFR expression and demonstrates a strong bystander effect in co-cultured EGFR-negative cells. In murine xenograft models, HMPL-A580 exhibited dose-dependent anti-tumor activity, suggesting a favorable therapeutic index compared to traditional antibody-drug conjugates.

The implications of this research extend to the broader field of precision oncology, particularly in the development of therapies targeting the PI3K/AKT/mTOR pathway. By integrating dual mechanisms of action through the ATTC platform, HUTCHMED is positioned to shift current research paradigms, potentially accelerating drug development timelines for therapies aimed at EGFR-driven malignancies. The anticipated results from ongoing clinical trials, including combinations with surufatinib, may further validate the therapeutic potential of HMPL-A580 and enhance treatment options for patients with challenging solid tumors.

Source: globenewswire.com